Vaccination against CD99 inhibits atherogenesis in low-density lipoprotein receptor-deficient mice

Cardiovascular Research

Volumn 78, Issue 3, 2008, Pages 590-596

  Van Wanrooij, Eva J A ^a   De Vos, Paula ^a   Bixel, M Gabriele ^b   Vestweber, Dietmar ^b   Van Berkel, Theo J C ^a   Kuiper, Johan ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b MAX PLANCK INSTITUTE FOR MOLECULAR BIOMEDICINE   (Germany)

Author keywords

Atherosclerosis; CD99; Diapedesis; DNA vaccination

Indexed keywords

CD69 ANTIGEN; CD8 ANTIGEN; CD99 ANTIGEN; DNA VACCINE; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; AORTA VALVE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CD8+ T LYMPHOCYTE; CELL COUNT; CELL ISOLATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DIETARY INTAKE; FEMALE; GENETIC TRANSFECTION; LEUKOCYTE COUNT; MEDIASTINUM LYMPH NODE; MOLECULAR CLONING; MOUSE; MOUSE STRAIN; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DOMAIN; SALMONELLA TYPHIMURIUM; SPLEEN LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; VACCINATION; VASCULAR ENDOTHELIUM;

3T3 CELLS; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ATHEROSCLEROSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FEMALE; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; MICE, KNOCKOUT; RECEPTORS, LDL; SALMONELLA TYPHIMURIUM; VACCINATION; VACCINES, ATTENUATED; VACCINES, DNA;

EID: 44449174450     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn025     Document Type: Article

References (31)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-1757.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695.
3. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-874.
4. Worthylake RA, Burridge K. Leukocyte transendothelial migration: orchestrating the underlying molecular machinery. Curr Opin Cell Biol 2001;13:569-577.
5. Weber C, Schober A, Zernecke A. Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 2004;24:1997-2008.
6. McEver RP, Cummings RD. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest 1997;100:S97-S103.
7. Tedder TF, Steeber DA, Pizcueta P. L-selectin-deficient mice have impaired leukocyte recruitment into inflammatory sites. J Exp Med 1995;181:2259-2264.
8. Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrone MA Jr. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 1987;84:9238-9242.
9. Vestweber D, Blanks JE. Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev 1999;79:181-213.
10. Ley K. The role of selectins in inflammation and disease. Trends Mol Med 2003;9:263-268.
11. Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991;251:788-791.
12. Collins RG, Velji R, Guevara NV, Hicks MJ, Chan L, Beaudet AL. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med 2000;191:189-194.
13. Nageh MF, Sandberg ET, Marotti KR, Lin AH, Melchior EP, Bullard DC et al. Deficiency of inflammatory cell adhesion molecules protects against atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1997;17:1517-1520.
14. Shih PT, Brennan ML, Vora DK, Territo MC, Strahl D, Elices MJ et al. Blocking very late antigen-4 integrin decreases leukocyte entry and fatty streak formation in mice fed an atherogenic diet. Circ Res 1999;84:345-351.
15. Muller WA, Weigl SA, Deng X, Phillips DM. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 1993;178:449- 460.
16. Martin-Padura I, Lostaglio S, Schneemann M, Williams L, Romano M, Fruscella P et al. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol 1998;142:117-127.
17. Bixel G, Kloep S, Butz S, Petri B, Engelhardt B, Vestweber D. Mouse CD99 participates in T-cell recruitment into inflamed skin. Blood 2004;104:3205-3213.
18. Bixel MG, Petri B, Khandoga AG, Khandoga A, Wolburg-Buchholz K, Wolburg H et al. A CD99-related antigen on endothelial cells mediates neutrophil but not lymphocyte extravasation in vivo. Blood 2007;109:5327- 5336.
19. Schenkel AR, Mamdouh Z, Chen X, Liebman RM, Muller WA. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol 2002;3:143-150.
20. Wegmann F, Petri B, Khandoga AG, Moser C, Khandoga A, Volkery S et al. ESAM supports neutrophil extravasation, activation of Rho, and VEGF-induced vascular permeability. J Exp Med 2006;203:1671-1677.
21. Huang MT, Larbi KY, Scheiermann C, Woodfin A, Gerwin N, Haskard DO et al. ICAM-2 mediates neutrophil transmigration in vivo: evidence for stimulus specificity and a role in PECAM-1-independent transmigration. Blood 2006;107:4721-4727.
22. Waclavicek M, Majdic O, Stulnig T, Berger M, Sunder-Plassmann R, Zlabinger GJ et al. CD99 engagement on human peripheral blood T cells results in TCR/CD3-dependent cellular activation and allows for Th1-restricted cytokine production. J Immunol 1998;161:4671-4678.
23. Wingett D, Forcier K, Nielson CP. A role for CD99 in T cell activation. Cell Immunol 1999;193:17-23.
24. Bernard G, Zoccola D, Deckert M, Breittmayer JP, Aussel C, Bernard A. The E2 molecule (CD99) specifically triggers homotypic aggregation of CD4+ CD8+ thymocytes. J Immunol 1995;154:26-32.
25. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002;8:1369-1375.
26. Babinska A, Azari BM, Salifu MO, Liu R, Jiang XC, Sobocka MB et al. The F11 receptor (F11R/JAM-A) in atherothrombosis: overexpression of F11R in atherosclerotic plaques. Thromb Haemost 2007;97:272-281.
27. Hauer AD, van Puijvelde GH, Peterse N, de Vos P, vanWeel V, vanWanrooij EJ et al. Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:2050-2057.
28. Lessner SM, Prado HL, Waller EK, Galis ZS. Atherosclerotic lesions grow through recruitment and proliferation of circulating monocytes in a murine model. Am J Pathol 2002;160:2145-2155.
29. Elrayess MA, Webb KE, Flavell DM, Syvanne M, Taskinen MR, Frick MH et al. A novel functional polymorphism in the PECAM-1 gene (53G>A) is associated with progression of atherosclerosis in the LOCAT and REGRESS studies. Atherosclerosis 2003;168:131-138.
30. Zernecke A, Liehn EA, Fraemohs L, von Hundelshausen P, Koenen RR, Corada M et al. Importance of junctional adhesion molecule-A for neointimal lesion formation and infiltration in atherosclerosis-prone mice. Arterioscler Thromb Vasc Biol 2006;26:e10-e13.
31. Chou CK, Hung JY, Liu JC, Chen CT, Hung MC. An attenuated Salmonella oral DNA vaccine prevents the growth of hepatocellular carcinoma and colon cancer that express alpha-fetoprotein. Cancer Gene Ther 2006;13:746-752.